MarketPulse
A

$APLS

2 articles found
2 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

RTW Investments Bets $193M on Apellis Rebound Despite 29% Stock Decline

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.
ARGXAPLSMDGLINSMinstitutional investmentbiotech investment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apellis to Highlight Complement Science Portfolio at TD Cowen Healthcare Forum

Apellis will discuss its complement-targeted drug portfolio at TD Cowen Healthcare Forum in March 2026, highlighting its approved therapies for eye and kidney diseases.
APLSbiopharmaceuticalApellis Pharmaceuticals